×

Treatment of tristetraproline (TTP) related diseases by inhibition of natural antisense transcript to TTP

  • US 9,611,477 B2
  • Filed: 09/09/2015
  • Issued: 04/04/2017
  • Est. Priority Date: 05/06/2009
  • Status: Active Grant
First Claim
Patent Images

1. A synthetic, modified oligonucleotide of 10 to 30 nucleotides in length comprising at least one modification wherein the at least one modification is selected from:

  • at least one modified sugar moiety;

    at least one modified internucleotide linkage;

    at least one modified nucleotide, and combinations thereof;

    wherein said oligonucleotide is an antisense compound which is at least 90% complementary to its target and is (i) is a single-stranded oligonucleotide of 10 to 30 nucleotides in length or (ii) is a siRNA of 19-30 nucleotides in length wherein both (i) and (ii) specifically hybridizes to a target comprising a complementary region of a natural antisense polynucleotide of a Tristetraproline (TTP) polynucleotide selected from the group consisting of SEQ ID NOS;

    3, 4 or 5 and upregulates the function and/or expression of a Tristetraproline (TTP) gene in vivo or in vitro as compared to a normal control wherein, when the oligonucleotide is a siRNA, said siRNA targets a non-overlapping, complementary region of said natural antisense polynucleotide.

View all claims
  • 1 Assignment
Timeline View
Assignment View
    ×
    ×